UNITED STATES | |||
SECURITIES AND EXCHANGE COMMISSION | |||
Washington, D.C. 20549 | |||
| |||
SCHEDULE 14A | |||
(Rule 14a-101) | |||
| |||
Proxy Statement Pursuant to Section 14(a) of | |||
| |||
Filed by the Registrant x | |||
| |||
Filed by a Party other than the Registrant o | |||
| |||
Check the appropriate box: | |||
o | Preliminary Proxy Statement | ||
o | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | ||
o | Definitive Proxy Statement | ||
x | Definitive Additional Materials | ||
o | Soliciting Material Pursuant to §240.14a-12 | ||
| |||
KALOBIOS PHARMACEUTICALS, INC. | |||
(Name of Registrant as Specified In Its Charter) | |||
| |||
| |||
(Name of Person(s) Filing Proxy Statement, if other than the Registrant) | |||
| |||
Payment of Filing Fee (Check the appropriate box): | |||
x | No fee required. | ||
o | Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. | ||
| (1) | Title of each class of securities to which transaction applies: | |
|
|
| |
| (2) | Aggregate number of securities to which transaction applies: | |
|
|
| |
| (3) | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): | |
|
|
| |
| (4) | Proposed maximum aggregate value of transaction: | |
|
|
| |
| (5) | Total fee paid: | |
|
|
| |
o | Fee paid previously with preliminary materials. | ||
o | Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. | ||
| (1) | Amount Previously Paid: | |
|
|
| |
| (2) | Form, Schedule or Registration Statement No.: | |
|
|
| |
| (3) | Filing Party: | |
|
|
| |
| (4) | Date Filed: | |
|
|
| |
On May 5, 2014, KaloBios Pharmaceuticals, Inc. (the “Company”) filed a Form 8-K with the Securities and Exchange Commission containing the following information.
Determination Not to Stand for Re-election
On May 1, 2014, at a regularly scheduled meeting of the board of directors of the Company, James I. Healy, MD, PhD, informed the board of directors that he does not intend to stand for re-election to the Company’s board of directors at the upcoming annual meeting of stockholders scheduled for June 18, 2014. Dr. Healy has served as a member of our board of directors and as chairman of the board since 2001. In light of the Company’s public offering in 2013 and his other present and potential public company board commitments, Dr. Healy has determined that this is an appropriate time for him to step down. Dr. Healy does not have a dispute with the Company over any matters, policy or otherwise. He will leave office as a director following the conclusion of the Company’s annual meeting.
Therefore, instead of nominating a slate of eight directors as previously disclosed in the Company’s proxy statement dated April 29, 2014 for the annual meeting of stockholders, the board of directors will be nominating a slate comprised of the seven remaining nominees set forth in the proxy statement. Shares represented by proxies returned before the annual meeting will be voted for the directors nominated by the board of directors as instructed, except that votes will not be cast for Dr. Healy because he is no longer standing for re-election to the Company’s board of directors. Your proxies cannot be voted for a greater number of persons than seven. The board of directors has reduced the size of the board to seven effective as of the conclusion of the annual meeting.
Board Leadership Changes
In connection with Dr. Healy’s decision not to stand for re-election to the Company’s board of directors, on May 1, 2014, the board of directors elected Ted W. Love, MD, as the Company’s new chairman of the board, effective immediately. Dr. Love has been a member of our board of directors since March 2009. He has held senior executive and management positions at a number of biopharmaceutical companies including Onyx Pharmaceuticals, Inc., Nuvelo, Inc., Theravance, Inc. and Genentech, Inc. Dr. Love also serves or has served as a member of the boards of directors of biopharmaceutical companies Santarus, Inc., Amicus, Inc., Adventrx, Inc., Affymax, Inc. and BioRad, Inc. and serves on the board of directors of Stanford Hospital & Clinics.
The board of directors also appointed Gary Lyons to serve on the audit committee effective immediately, to replace Dr. Love, who will step down in connection with his appointment as chairman of the board. It also appointed V. Bryan Lawlis, Jr., Ph.D. and Laurie Smaldone Alsup, M.D., to the nominating and corporate governance committee, effective immediately.
Board Compensation Changes
On May 1, 2014, the board of directors also revised the equity compensation component of the Company’s board of director compensation program described in the Company’s proxy statement dated April 29, 2014, such that continuing directors will be eligible to receive an annual option to purchase 20,000 shares of our common stock rather than 10,000 shares. Such annual option grants are made effective immediately following the completion of our annual meeting of stockholders and vest ratably over 12 months of continuous service following the date of grant.
